Skip to content

A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP

A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP: Comparison of EST, EPBD, and sEST+EPBD in Endoscopic Choledocholithiasis Treatment.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03416205
Enrollment
450
Registered
2018-01-31
Start date
2017-07-20
Completion date
2021-09-01
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ERCP

Brief summary

Endoscopic retrograde cholangiopancreatography (ERCP) is commonly performed to remove bile duct stones.Endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), and endoscopic sphincterotomy plus balloon dilation (sEST+EPBD) are 3 methods used to enlarge the papillary orifice, but their efficacy and safety remains controversial. This study aimed to compare these methods for treating common bile duct (CBD) stones.

Detailed description

Investigators first divided the patients with different sizes of common bile duct stones into two groups. The bile duct stone diameter of group A is less than 1.0cm while group B is more than 1.0cm and less than 1.5cm. Each group compared Endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), and endoscopic sphincterotomy plus balloon dilation (sEST+EPBD) in ERCP. Through the postoperative comparison of relevant inspection test indicators, the recovery of patients, whether the occurrence of complications, including infection,bleeding,pancreatitis,perforation , and 1 year stone recurrence rate,Investigators assess the advantages and disadvantages in three different strategies in different sizes of common bile duct stones , and finally get a relatively objective evaluation to guide our daily ERCP work on the choice of duodenal papillary sphincter treatment strategy.

Interventions

DEVICEErbao electric knife

Erbao electric knife is used to cut the Duodenal sphincter

DEVICEThree-cavity incision knife

Three-cavity incision knife is used to cut the Duodenal sphincter

DEVICEColumnar expansion balloon

Columnar expansion balloon is used to expand the the Duodenal sphincter

Sponsors

Nanfang Hospital, Southern Medical University
CollaboratorOTHER
Zhujiang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 20-80 years old * CT or MRCP diagnose the patients with Common bile duct stones * The diameter of the stone is less than or equal to 1.5cm * Patients with the indications for ERCP * Patients and their families agree to participate in the trial

Exclusion criteria

* Stones are too large (\> 1.5cm) * A history of gastrointestinal surgery * ERCP and EST or EPBD surgery history * Patients generally poor, total bilirubin\> 200umol / L or PT time extension\> 3s * Patients with mental illness or other serious heart and lung disease

Design outcomes

Primary

MeasureTime frameDescription
the incidence of composite events of infection, hemorrhage, perforation, pancreatitis3 and 24 hours after the ERCPInvestigators comprehensively assess whether the hemorrhage, perforation, pancreatitis and other complications of retrograde cholangiopancreatography (ERCP) happen or not by clinical sympton and blood index 1 day after the ERCP. The blood index includes CRP, amylase,lipase,leukocyte,red blood cell,hemoglobin.Besides,CT will be done if necessary.Finally investigators use statistical method to analyse the incidence of composite events of infection, hemorrhage, perforation, pancreatitis.

Secondary

MeasureTime frameDescription
Recurrence rate of bile duct stones1 year after the ERCP.One year after the ERCP,the participants will have a CT scan to find out whether the bile duct stones recur again.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026